ACRS Q1 2023 Earnings — Aclaris Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ACRSAclaris Therapeutics, Inc.

$435M

Q1 2023 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$3M+74.0% YoY

Gross Profit

$659,00026.1% margin

Operating Income

-$30M-1183.5% margin

Net Income

-$28M-1113.9% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

-67.4%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$27M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$230M

Total Liabilities

$53M

Stockholders' Equity

$177M

Cash & Equivalents

$45M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$1M	+74.0%
Gross Profit	$659,000	$298,000	+121.1%
Operating Income	-$30M	-$19M	-58.2%
Net Income	-$28M	-$19M	-49.9%

Revenue Segments

License and Service

$2M65%

Contract research

$889,00035%